Cancer Research Meeting Calendar  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vimalachandran, D.
Right arrow Articles by Costello, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vimalachandran, D.
Right arrow Articles by Costello, E.
[Cancer Research 65, 3218-3225, April 15, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

High Nuclear S100A6 (Calcyclin) Is Significantly Associated with Poor Survival in Pancreatic Cancer Patients

Dale Vimalachandran1, William Greenhalf1, Christopher Thompson1, Jutta Lüttges4, Wendy Prime2, Fiona Campbell3, Andrew Dodson3, Richard Watson1, Tatjana Crnogorac-Jurcevic5, Nicholas Lemoine5, John Neoptolemos1 and Eithne Costello1

1 Division of Surgery and Oncology and 2 Cancer Tissue Bank Research Centre, Department of Pathology, University of Liverpool; 3 Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom; 4 Department of Pathology, University of Schleswig-Holstein, Kiel, Germany; and 5 Cancer Research UK Clinical Centre, Queen Mary's School of Medicine at Barts and The London, London, United Kingdom

Requests for reprints: Eithne Costello, Division of Surgery and Oncology, University of Liverpool, Royal University Hospital, Daubly Street, Liverpool, Merseyside, United Kingdom. Phone: 44-151-706-4178; E-mail: ecostell{at}liv.ac.uk.

Recent studies have reported elevated levels of S100A6 in pancreatic ductal adenocarcinoma cells. Here, we describe a detailed analysis of S100A6 expression in benign (n = 32), malignant (n = 60), and premalignant pancreatic ductal cells [96 pancreatic intraepithelial neoplasias (PanIN) from 46 patients]. S100A6 staining was more intense in malignant cells than in benign cells (P = 0.0001). In malignant cells, staining was higher in the nucleus than in the cytoplasm (P = 0.003). Univariate analysis revealed a significant decrease in survival time for patients with high levels of nuclear (P = 0.01) but not cytoplasmic (P = 0.20) S100A6. No evidence was found for an association between nuclear S100A6 expression and other variables, including gender, age at surgery, tumor size or grade, nodal metastases, resection margin, vascular invasion, perineural invasion, p53 or Smad4 levels (both linked to survival in previous studies), or the p65 subunit of nuclear factor-{kappa}B (a potential regulator of S100A6). Although nodal metastases and resection margin involvement were also associated with poor survival (P = 0.06 in both cases), multivariate analysis suggests that nuclear S100A6 is a significant independent indicator of survival (P = 0.003). Whereas PanIN 1a lesions showed a general absence of S100A6 staining, there was a progressive increase in the proportion of positively stained PanINs with increasing PanIN grade. In particular, we observed an increase in the frequency and intensity of nuclear staining. Our results suggest that up-regulation of S100A6 is an early event in pancreatic cancer development and that elevated levels of nuclear S100A6 may affect clinical outcome.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Hu, M. Arellano, P. Boontheung, J. Wang, H. Zhou, J. Jiang, D. Elashoff, R. Wei, J. A. Loo, and D. T. Wong
Salivary Proteomics for Oral Cancer Biomarker Discovery
Clin. Cancer Res., October 1, 2008; 14(19): 6246 - 6252.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
M. Ouaissi, I. Sielezneff, R. Silvestre, B. Sastre, J.-P. Bernard, J. S. Lafontaine, M. J. Payan, L. Dahan, N. Pirro, J. F. Seitz, et al.
High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the Pancreas
Ann. Surg. Oncol., August 1, 2008; 15(8): 2318 - 2328.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
L. M. Orre, M. Pernemalm, J. Lengqvist, R. Lewensohn, and J. Lehtio
Up-regulation, Modification, and Translocation of S100A6 Induced by Exposure to Ionizing Radiation Revealed by Proteomics Profiling
Mol. Cell. Proteomics, December 1, 2007; 6(12): 2122 - 2131.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. J. Whiteman, M. E. Weeks, S. E. Dowen, S. Barry, J. F. Timms, N. R. Lemoine, and T. Crnogorac-Jurcevic
The Role of S100P in the Invasion of Pancreatic Cancer Cells Is Mediated through Cytoskeletal Changes and Regulation of Cathepsin D
Cancer Res., September 15, 2007; 67(18): 8633 - 8642.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Ohuchida, K. Mizumoto, J. Yu, H. Yamaguchi, H. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi, and M. Tanaka
S100A6 Is Increased in a Stepwise Manner during Pancreatic Carcinogenesis: Clinical Value of Expression Analysis in 98 Pancreatic Juice Samples
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 649 - 654.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
C C Thompson, F J Ashcroft, S Patel, G Saraga, D Vimalachandran, W Prime, F Campbell, A Dodson, R E Jenkins, N R Lemoine, et al.
Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility
Gut, January 1, 2007; 56(1): 95 - 106.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
R. Frances, J. R. Tumang, and T. L. Rothstein
Extreme skewing of annexin II and S100A6 expression identified by proteomic analysis of peritoneal B-1 cells
Int. Immunol., January 1, 2007; 19(1): 59 - 65.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.